04415674 1.7.12 30.6.13 30.6.13 Company accounts Private Limited Company FY true false true false true false false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure044156742012-06-30044156742013-06-30044156742012-07-012013-06-30044156742011-06-30044156742011-07-012012-06-30044156742012-06-3004415674ns12:England2012-07-012013-06-3004415674ns14:PoundSterling2012-07-012013-06-3004415674ns7:Director12012-07-012013-06-3004415674ns7:OrdinaryShareClass12012-07-012013-06-3004415674ns7:Director32012-07-012013-06-3004415674ns7:Director42012-07-012013-06-3004415674ns7:RegisteredOffice2012-07-012013-06-3004415674ns7:EntityAccountantsOrAuditors2012-07-012013-06-3004415674ns5:PlantMachinery2012-07-012013-06-3004415674ns5:FixturesFittings2012-07-012013-06-3004415674ns5:MotorVehicles2012-07-012013-06-3004415674ns7:OrdinaryShareClass12013-06-3004415674ns7:OrdinaryShareClass12012-06-30
REGISTERED NUMBER: 04415674 (England and Wales)
















ABBREVIATED UNAUDITED ACCOUNTS

FOR THE YEAR ENDED 30 JUNE 2013

FOR

INNOVA BIOSCIENCES LIMITED

INNOVA BIOSCIENCES LIMITED (REGISTERED NUMBER: 04415674)

CONTENTS OF THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2013










Page

Company Information 1

Abbreviated Balance Sheet 2

Notes to the Abbreviated Accounts 3

INNOVA BIOSCIENCES LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2013







DIRECTORS: Dr Nicolas Steven Gee
Mr Tim Matthew Bernard
Dr Andrew Charles Lane





REGISTERED OFFICE: Babraham Hall
Babraham
CAMBRIDGE
Cambridgeshire
CB22 3AT





REGISTERED NUMBER: 04415674 (England and Wales)





ACCOUNTANTS: Staffords
Chartered Accountants
CPC1
Capital Park
Fulbourn
CAMBRIDGE
Cambridgeshire
CB21 5XE
Page 1
INNOVA BIOSCIENCES LIMITED (REGISTERED NUMBER: 04415674)

ABBREVIATED BALANCE SHEET
30 JUNE 2013

2013 2012
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 2 49,671 61,148

CURRENT ASSETS
Stocks 168,563 146,338
Debtors 259,394 309,433
Cash at bank 286,285 343,892
714,242 799,663
CREDITORS
Amounts falling due within one year 116,946 182,966
NET CURRENT ASSETS 597,296 616,697
TOTAL ASSETS LESS CURRENT
LIABILITIES
646,967
677,845

CAPITAL AND RESERVES
Called up share capital 3 142,205 142,205
Share premium 355,642 355,642
Profit and loss account 149,120 179,998
SHAREHOLDERS' FUNDS 646,967 677,845

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2013.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2013 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies
Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections
394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.


The financial statements were approved by the Board of Directors on 16 January 2014 and were signed on its behalf by:





Dr Nicolas Steven Gee - Director


The notes form part of these abbreviated accounts

Page 2
INNOVA BIOSCIENCES LIMITED (REGISTERED NUMBER: 04415674)

NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2013


1. ACCOUNTING POLICIES

Accounting convention
The financial statements have been prepared under the historical cost convention and in accordance with the
Financial Reporting Standard for Smaller Entities (effective April 2008).

Turnover
Turnover represents net invoiced sales of services, excluding value added tax.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost
Fixtures and fittings - 25% on cost
Motor vehicles - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow
moving items.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance
sheet date.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension
scheme are charged to the profit and loss account in the period to which they relate.

2. TANGIBLE FIXED ASSETS
Total
£   
COST
At 1 July 2012 161,681
Additions 22,908
Disposals (12,883 )
At 30 June 2013 171,706
DEPRECIATION
At 1 July 2012 100,533
Charge for year 29,336
Eliminated on disposal (7,834 )
At 30 June 2013 122,035
NET BOOK VALUE
At 30 June 2013 49,671
At 30 June 2012 61,148

Page 3 continued...
INNOVA BIOSCIENCES LIMITED (REGISTERED NUMBER: 04415674)

NOTES TO THE ABBREVIATED ACCOUNTS - continued
FOR THE YEAR ENDED 30 JUNE 2013


3. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2013 2012
value: £    £   
142,205 Ordinary £1 142,205 142,205

There are currently both unapproved and approved option schemes in place within the company as follows:

Unapproved options for the directors over 2,420 shares at an exercise price of £5.10 granted in December 2005.

A total pool of EMI approved options over 12,420 shares at exercise prices of between £5.10 and £25.00,
granted between August 2006 and November 2012. Following the year end 1,125 of these options were
exercised and 375 lapsed, following the departure of an employee.

4. RESEARCH AND DEVELOPMENT EXPENSES

During the year the company spent a total of £180,336 (2011: 119,287) on Research and development activities.

Page 4